Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A proof of concept study evaluating the potential benefit of Liquid Alpha-1 Antitrypsin (AAT) on liver preservation prior to transplantation.

Trial Profile

A proof of concept study evaluating the potential benefit of Liquid Alpha-1 Antitrypsin (AAT) on liver preservation prior to transplantation.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2018

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Graft-versus-host disease; Liver transplant rejection
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 05 Sep 2018 Results from the first cohort will be submitted for publication later this year, according to a Kamada media release.
    • 05 Sep 2018 According to a Kamada media release, positive results were obtained from first cohort and the second cohort of the study will be initiated shortly and will assess the effect of AAT with different dosing. Company plans further extension of the study to other solid organs transplantations, if this trial results are positive.
    • 23 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top